Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody drug conjugates in breast cancer in China: Highlights, challenges, and prospects
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-11-04
DOI
10.1002/cncr.35093
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
- (2023) Limin Zou et al. Cancer Communications
- Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
- (2023) Chenchen Ji et al. ONCOLOGIST
- Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
- (2023) G. Antonarelli et al. ESMO Open
- Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
- (2023) Andrea D’Arienzo et al. EClinicalMedicine
- Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
- (2022) Giampaolo Bianchini et al. Cancers
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition
- (2022) Xinwei Liu et al. CANCER CELL
- The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
- (2022) Claudia von Arx et al. CANCER TREATMENT REVIEWS
- Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
- (2022) Yu‐Fei Chen et al. Cancer Communications
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
- (2020) Mark Barok et al. CANCER LETTERS
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ado-trastuzumab Emtansine
- (2014) Patricia A. Corrigan et al. ANNALS OF PHARMACOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now